Telerobotic surgery is moving from isolated demonstrations toward broader clinical and regulatory development, putting SS Innovations International (NASDAQ: SSII) and its founder and CEO, cardiac surgeon Dr. Sudhir Srivastava, in an increasingly relevant part of the surgical robotics market. A recent MedTech Dive report, “Telerobotic surgery is advancing around the world. Will the US embrace it?,” examined the technology’s development and the regulatory and infrastructure questions surrounding remote surgery, and highlighted SS Innovations alongside larger medical-device companies and emerging robotics developers.
For SS Innovations, the discussion comes as its SSi Mantra system is accumulating experience in telesurgery. Dr. Srivastava told MedTech Dive that robotic surgery is inherently a form of teleoperation and that the central technical question is how much distance can be introduced without compromising responsiveness. As of September 28, 2026, the company reported 195 robotic telesurgeries using the SSi Mantra system, including cardiac procedures and long-distance operations.
The company’s installed base reached 244 SSi Mantra systems as of September 28, up 45% from the end of 2025, while cumulative procedures reached 14,503. The system has expanded into 12 countries, with recent cardiac-surgery programs launched in Colombia and Sri Lanka and a new program established at HCG Hospital in Ahmedabad. SS Innovations is currently pursuing U.S. FDA clearance and European Union CE marking as it seeks to expand the system into additional international markets.
These developments matter because telerobotic surgery could extend access to specialized surgical care beyond major medical centers, allowing expert surgeons to operate remotely on patients in underserved or distant locations. The technology’s progress also raises important regulatory and infrastructure questions, particularly in the United States, where adoption of remote procedures has lagged some other regions.
SS Innovations’ growing procedure volume and international footprint position it as a notable player in this evolving field. The company’s pursuit of FDA clearance and CE marking underscores the potential for broader market acceptance if regulatory hurdles are cleared. The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII.
As telerobotic surgery gains ground, SS Innovations’ experience with the SSi Mantra system may offer insights into the practical challenges and opportunities of remote procedures. The company’s progress will be closely watched by investors and industry observers assessing the future of surgical robotics. For more details, see the original release on www.newmediawire.com.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer.
